



Published in final edited form as:

Nature. 2015 January 22; 517(7535): 489–492. doi:10.1038/nature13898.

The mutational landscapes of genetic and chemical models of *Kras*-driven lung cancer

Peter M. K. Westcott^{1,2}, Kyle D. Halliwill^{1,2}, Minh D. To¹, Mamunur Rashid³, Alistair G. Rust³, Thomas M. Keane³, Reyno Delrosario¹, Kuang-Yu Jen⁴, Kay E. Gurley⁵, Christopher J. Kemp⁵, Erik Fredlund⁶, David A. Quigley¹, David J. Adams³, and Allan Balmain^{1,7,*}

¹Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94158, USA

²Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California 94158, USA

³Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1HH, UK

⁴Department of Pathology, University of California San Francisco, San Francisco, California 94143, USA

⁵Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA

⁶Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Stockholm 171 21, Sweden

⁷Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California 94158, USA

SUMMARY

Next-generation sequencing of human tumours has refined our understanding of the mutational processes operative in cancer initiation and progression, yet major questions remain regarding factors that induce driver mutations, and the processes that shape their selection during tumorigenesis. We performed whole-exome sequencing (WES) on adenomas from three mouse models of non-small cell lung cancer (NSCLC), induced by exposure to carcinogens (Methyl-nitrosourea (MNU) and Urethane), or by genetic activation of *Kras* (*Kras*^{LA2}). Although the MNU-induced tumours carried exactly the same initiating mutation in *Kras* as seen in the *Kras*^{LA2}

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

*Correspondence: abalmain@cc.ucsf.edu.

AUTHOR CONTRIBUTIONS

P.M.K.W., K.D.H., M.D.T., D.J.A. and A.B contributed to the overall study design. P.M.K.W. carried out most of the experiments, with help from M.D.T. R.D. was responsible for all of the animal studies. Sequencing and Sequenom were performed at the Sanger Institute under the supervision of D.J.A., and data processing was carried out by K.D.H, M.R., A.G.R., and T.M.K. SNV and CNA calling were carried out by K.D.H. Data analysis was carried out primarily by P.M.K.W and K.D.H, with help from E.F. and D.A.Q. K-Y J. made histological assessments of all tumours. Adenomas and adenocarcinomas from the *A/J* mice were provided by C.J.K. and K.E.G. The manuscript was written primarily by P.M.K.W. and A.B., with contributions from the other authors.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

model (G12D), MNU tumours had an average of 192 non-synonymous, somatic single nucleotide variants (SNVs), compared to only 6 in tumours from the *Kras*^{LA2} model. In contrast, the *Kras*^{LA2} tumours exhibited a significantly higher level of aneuploidy and copy number alterations (CNAs) compared to the carcinogen-induced tumours, suggesting that carcinogen and genetically-engineered models adopt different routes to tumour development. The wild type (WT) allele of *Kras* has been shown to act as a tumour suppressor in mouse models of NSCLC. We demonstrate that urethane-induced tumours from WT mice carry mostly (94%) Q61R *Kras* mutations, while those from *Kras* heterozygous animals carry mostly (92%) Q61L mutations, indicating a major role of germline *Kras* status in mutation selection during initiation. The exome-wide mutation spectra in carcinogen-induced tumours overwhelmingly display signatures of the initiating carcinogen, while adenocarcinomas acquire additional C>T mutations at CpG sites. These data provide a basis for understanding the conclusions from human tumour genome sequencing that identified two broad categories based on relative frequency of SNVs and CNAs¹, and underline the importance of carcinogen models for understanding the complex mutation spectra seen in human cancers.

Sequencing studies of human cancers have identified a number of mutation “signatures”, suggesting that tumours carry an imprint of the environmental agents to which patients were exposed²⁻⁴. There are presently no studies of genome-wide carcinogen signatures in any mouse cancer models, despite widespread use of these models in studies of cancer. To address the importance of engineered versus carcinogen-induced mutations, we investigated the mutations in mouse NSCLC arising as a result of spontaneous oncogenic activation of *Kras* (*Kras*^{LA2})⁵, or exposure to urethane or MNU⁶. Both carcinogens initiate lung tumourigenesis by oncogenic mutation of *Kras*, which is frequently mutated in human NSCLC⁷. WES was performed on 82 *FVB/N* lung adenomas, 44 induced by urethane, 26 by MNU, and 12 by the *Kras*^{LA2} allele (Extended Data Table 1). To study the tumour suppressive role of WT *Kras*, we included mice with one functionally null *Kras* allele, *Kras*^{+/*LSL-G12D*} (see methods)⁸, hereafter referred to as *Kras*^{+/-}. Importantly, these mice develop larger and more tumours than WT littermates following carcinogen treatment^{9,10}.

Carcinogen-induced tumours had far more SNVs than *Kras*^{LA2} tumours (Fig. 1a), with an average of 728 and 185 in MNU- and urethane-induced tumours, respectively, and 47 in *Kras*^{LA2} tumours. This is similar to findings in humans where lung tumours from smokers contained orders of magnitude more SNVs than tumours from non-smokers¹¹. We performed hierarchical clustering on the 96 possible SNVs, classified by trinucleotide context and substitution³, and tumours cluster perfectly by treatment (Fig. 1b), underscoring distinct mutational spectra. Highly consistent signatures are apparent across all tumours of each carcinogen group (Fig. 1c and Extended Data Fig. 1a-b), in agreement with the known A>T, A>G, and G>A substitutions induced by urethane¹², and G>A transitions induced by MNU¹³. The elevated SNV burden and clear carcinogen imprint show that most SNVs were induced during the period of carcinogen activity following administration. In contrast, *Kras*^{LA2} tumours showed no notable signatures (Extended Data Fig. 1c).

A highly significant 5'-flanking purine bias and 3'-flanking thymidine bias for G>A transitions was identified in the MNU-induced tumours (Extended Data Fig. 2a). Indeed,

GGT>A is the most frequent SNV in this group. In urethane-induced tumours, a slight bias for 3'-cytidine in A>G transitions and 3'-guanosine in A>T transversions was seen (Extended Data Fig. 2b-c), while G>A transitions were also common (Extended Data Fig. 2d). The most frequent SNVs in *Kras*^{LA2} tumours were CGN>A (or the complement, NCG>T) (Extended Data Fig. 2e). Importantly, CGN>A is a signature of genomic instability in cancer and normal cells^{3,14,15}.

In concordance with MNU's propensity to induce GGT>A transitions, 25/26 MNU-induced lung tumours carried this transition in codon 12 of *Kras*, resulting in a G12D mutation, while all 44 urethane-induced tumours harbored *Kras* Q61 mutations (SI Table 1). Histological evaluation revealed the expected tumour types (Extended Data Fig. 3a), and solid tumours were significantly enriched in the MNU and *Kras*^{LA2} groups, which share the *Kras* G12D mutation (Extended Data Fig. 3b). It is possible that *Kras* G12D initiates a pathway to solid NSCLC that is distinct from that initiated by Q61 mutants. Alternatively, urethane may induce *Kras* mutations in a different population of tumour-initiating cells. Remarkably, urethane-induced tumours from *WT* mice had almost exclusively *Kras* Q61R mutations, while tumours from *Kras*^{+/-} mice had almost exclusively Q61L mutations (Extended Data Fig. 4a-b). This switch is not likely due to differences in carcinogen metabolism or DNA repair, as neither the overall mutation spectra (Extended Data Fig. 1b) nor the exome-wide rates of the causative Q61R and Q61L substitutions (Extended Data Fig. 4c) differed between tumours of the two genotypes. This suggests that *Kras* Q61R and Q61L are functionally distinct, and selection of cells harboring these oncoproteins is modulated by WT *Kras*. Intriguingly, in the single instance of a *Kras* Q61L mutant tumour from a *WT* mouse, a *Kras* loss-of-function mutation (T35A)^{16,17} was also found, potentially inactivating the *WT* allele. Although *KRAS* Q61 mutations are relatively rare in human lung cancer, further investigation of the Q61 switch may yield valuable insights into *RAS* mutation selection, and the interplay of *RAS* oncogenes and their proto-oncogenes. While further studies are needed to identify the mechanism of this selection, we conclude that *Kras* mutations are not only carcinogen-dependent, but are influenced by germline differences that alter the expression of WT *Kras*.

We focused our search for additional driver mutations on genes known to harbor *bona fide* driver mutations in human cancers^{18,19} (see Methods). 65 consequential SNVs in 49 of these genes were validated (Extended Data Table 2), most involving amino acids conserved between mouse and human. SNVs in *Akt1*, *Atm*, *Rnf43*, *Notch1*, *Ret*, and *Rb1*, in particular, occurred at positions homologous to mutations in human cancers (SI Table 2). Two nonsense and two missense mutations were found in *Mtus1*, a candidate tumour suppressor gene in multiple cancers²⁰⁻²³. In concordance with its role as a tumour suppressor, knockdown of *Mtus1* accelerated growth in a mouse lung cancer cell line driven by *Kras* G12D (Extended Data Fig. 5a-b). In addition, *MTUS1* expression is significantly and positively associated with overall survival across all stages in human lung adenocarcinoma (TCGA LUAD RNA-seq, n = 354) (Extended Data Fig. 5c; SI Table 3). This association was validated in an independent human lung adenocarcinoma dataset²⁴ (SI Table 3).

The observation that *Kras*^{LA2} tumours have on average 15-fold fewer SNVs than MNU-induced tumours (Fig. 1b), despite sharing similar histology and the same *Kras* mutation,

suggested there are additional factors influencing tumorigenesis in these samples. Indeed, we found that CNAs are widespread in *Kras*^{LA2} tumours (average = 3.25) but infrequent in carcinogen-induced tumours (average = 0.07), and hierarchical clustering by copy-number profile clearly segregated the carcinogen-induced and *Kras*^{LA2} tumours into different groups (Fig. 2). Most *Kras*^{LA2} tumours (9/12) showed amplification of *Kras*, mainly via gain of one copy of chromosome 6. These tumours also carried common gains on chromosomes 2, 10, 12, 15, and 17, and deletions on chromosomes 4, 9, 11, and 17 (Extended Data Fig. 6), consistent with previously published aCGH results from the *Kras*^{LA2} model²⁵. In contrast, carcinogen-induced tumours had very few CNAs and aneuploidies.

A summary of SNVs and CNAs involving driver genes reveals that all SNVs occurred in carcinogen-induced tumours and overwhelmingly showed the signature of the initiating carcinogen (Fig. 3). This suggests that carcinogen models produce tumours with a diversity of potential secondary driver SNVs, recapitulating in part the mutational heterogeneity seen in human cancer. One MNU-induced tumour harbored an E40K mutation in *Akt1*, generating a constitutively active oncoprotein²⁶, and an early nonsense mutation in the tumour suppressor gene *Pax5*. Together with *Kras* G12D, this tumour had three functional mutations in cancer drivers, all MNU signature mutations likely induced in the same cell following MNU treatment. Although the *Kras*^{LA2} tumours had no SNVs in established driver genes, some exhibited CNAs involving driver genes mutated in the carcinogen-induced tumours (Fig. 3). Further evidence for the role of CNAs in genetically-engineered mouse models of cancer is provided by a recent report showing that mouse small-cell lung cancers induced by inactivation of *Trp53* and *Rb1* exhibit many CNAs, but a paucity of SNVs²⁷. Similarly, mouse lung tumours induced by Cre-activation of *Kras*^{LSL-G12D} exhibit extremely few exome-wide SNVs (personal communication, Tyler Jacks). We conclude that carcinogen and genetic models show fundamental differences in patterns of genomic alterations, and that the requirement for CNAs may be abrogated by the high frequency of carcinogen-induced SNVs—a reciprocal relationship also seen in a recent analysis of TCGA sequencing of several thousand human tumours¹.

To understand the processes operative in progression to adenocarcinoma, we performed WES on 9 *FVB/N* and 13 *A/J* strain urethane-induced, histologically-confirmed lung adenocarcinomas (Extended Data Fig. 7a-b). The observed urethane-signature A>G and A>T substitutions recapitulate the rates and patterns seen in the adenomas with remarkable fidelity (Extended Data Fig. 8), validating the utility of mouse carcinogen models to resolve complex mutational spectra. Further analysis revealed a significant increase of the CGN>A signature of genomic instability in both *FVB/N* and *A/J* adenocarcinomas (Fig. 4). This elevation cannot be attributed solely to tumour age, as the *FVB/N* adenocarcinomas and adenomas were harvested following the same 20-week protocol.

Most adenocarcinomas harbored Q61R mutations in *Kras* (SI Table 4). Although urethane is known to induce *Kras* Q61L lung adenomas in *A/J* mice, adenocarcinomas from these animals harbor predominantly *Kras* Q61R mutations²⁸. Eleven additional SNVs in driver genes were identified, as well as 3 SNVs in the reported mouse lung adenoma suppressor gene *Fat4*²⁹ (SI Table 5). Compared to the urethane-induced adenomas, the adenocarcinomas are enriched for tumours with SNVs in high-likelihood driver genes other

than *Kras* (Fisher $p = 0.046$), as well as tumours harboring CGN>A transitions in these genes (Fisher $p = 0.034$). These data suggest that CGN>A transitions may play a role in progression of adenomas to adenocarcinomas.

A comparison of all validated carcinogen-induced mouse mutations with WES of human lung adenocarcinoma (TCGA LUAD, $n = 230$) revealed substantial overlap in driver genes harboring consequential mutations, both overall and in *KRAS*-mutant tumours (SI Table 6). Some of the most frequently mutated genes in the mouse tumours (*Arid1b*, *Atm*, *Crebbp*, *Mll2*, *Rb1*) were also frequently mutated in the human tumours. Many of the mouse mutations occurred near mutations identified in TCGA LUAD, including functional mutations in *Akt1*, *Atm*, and *Cbl* (SI Table 7). In addition, the driver genes *ALK*, *APC*, *JAK2*, *MET*, and *NF1*, commonly mutated in human NSCLC¹¹, were mutated in the mouse tumours. Finally, an analysis of *MTUS1* mutations in TCGA LUAD revealed only consequential mutations (1.7%)—two missense mutations, and two frameshift deletions—suggesting that loss-of-function mutations in *MTUS1* may be selected for in a subset of lung adenocarcinomas.

Genomic analysis of mouse tumours induced by a range of carcinogens may help reveal the relationships between environmental exposures and tumour architecture. Models that encompass heterogeneity in both genetic background and carcinogen exposure may also be useful for preclinical testing of cancer therapeutics, as the diversity of germline and somatic SNVs may recapitulate variation in drug response and resistance observed in human clinical trials. Importantly, carcinogen models enable production of tumours with a range of initiating *Ras* lesions, providing a valuable resource for interrogating the specificity and idiosyncrasies of these different mutations.

METHODS

Mouse strains and tumour induction

Kras^{LA2} and *Kras*^{LSL-G12D} alleles, originally on a *C57BL6/129/SvJae* background, were backcrossed onto the *FVB/N* genetic background for more than 20 generations. Mice were treated with urethane (1 g/kg) or MNU (50 mg/kg) dissolved in PBS by intraperitoneal injection at ~7–12 weeks of age. Lung tumours from mice induced with carcinogen were harvested at ~20 weeks after injection, or ~32 weeks in the *A/J* animals, while spontaneous lung tumours were collected from *Kras*^{LA2} mice at ~9 months of age. For the urethane-induced adenomas, 18 tumours from 7 *WT* animals and 26 tumours from 9 *Kras*^{LSL-G12D} animals were collected. For the MNU treatment group, 5 tumours from 4 *WT* animals and 21 tumours from 3 *Kras*^{LSL-G12D} animals were collected. A total of 12 tumours were collected from 4 *Kras*^{LA2} animals. 8 histologically confirmed adenocarcinomas were collected from 4 *FVB/N Kras*^{LSL-G12D} animals, and 1 from a *WT FVB/N* animal. 13 tumours, including 10 histologically confirmed adenocarcinomas, were collected from 7 *WT A/J* animals. *Kras*^{LSL-G12D} is a latent G12D allele that is inactive in the absence of Cre-recombinase. Importantly, lungs from *Kras*^{LSL-G12D} heterozygous mice were shown to have an approximately 2-fold reduction of *Kras* mRNA transcript and protein compared to *WT* littermates³⁰. Furthermore, these mice had more and larger lung tumours than *WT* mice

following carcinogen treatment³⁰, similar to results seen for animals heterozygous for the original *Kras* null allele³¹.

No animals or tumours were excluded from the analysis. Tumours were collected from male and female mice, and no sex differences were observed. No formal randomization was performed, and all analyses were performed against the entire set of data in an unbiased manner. All animal experiments were approved by the University of California San Francisco Laboratory Animal Resource Center.

DNA Isolation and sequencing

Formalin-fixed or flash-frozen tumours free of visible normal tissue were digested overnight in proteinase K (Biolone) and phenol/chloroform purified using 5 PRIME Phase Lock Gel Heavy Tubes (Fisher Scientific). Integrity of genomic DNA was assessed by electrophoresis on 1% agarose gels, and concentration was determined by nanodrop spectrophotometry and PicoGreen (Invitrogen). Exome enrichment and sequencing genomic libraries were prepared using the Illumina Paired End Sample Prep Kit following manufacturer instructions. Enrichment was performed as described previously³² using the Agilent SureSelect Mouse All Exon kit following the manufacturer's recommended protocol. Each exome was sequenced using a 76bp paired-end protocol on the Illumina platform (GAII or HiSeq2000).

Sequence alignment, processing and quality control

Tumour.bam files were aligned to the GRCm38/mm10 version of the *Mus musculus* genome using BWA (version 0.5.9)³³. After alignment, duplicates were marked and mate information was fixed using Picard (version 1.80; <http://picard.sourceforge.net/>). We then recalibrated base quality score and realigned reads around indels using GATK (version 2.2–15)³⁴. Finally, alignment and coverage metrics were collected using Picard. We sequenced an average of 75 million unique on-target reads per tumour. Targeted bases were sequenced to a mean depth of 72, and greater than 88% of targeted bases were sequenced to 20X coverage or greater. There were no significant differences in depth of coverage or proportion of regions covered to 20X between tumour induction groups.

Identification of SNVs and annotation

SNVs were identified using the somatic variant detection program, MuTect (version 1.1.4)³⁵. Tumours were called against DNA taken from normal tail isolated from two *WT FVB/N* control samples. GRCm38/mm10 served as the reference during calling. Each set of variants was then subset to those variants that passed MuTect filters and had a minimum read depth of 12. The intersection of both callsets was then filtered for known variants from the database of mouse variation available at <ftp-mouse.sanger.ac.uk> (release 1303, mgp.v3). Variants found only in *Mus spretus*, *Mus castaneus*, or *Mus musculus musculus* were not used for filtration. All samples were also filtered for variants observed in a panel of six controls. These comprised the two *WT* samples used for variant calling, two *Kras^{LA2}* mice, and two *Kras^{LSL-G12D}* heterozygous mice. These mice were then called for variants using FreeBayes (version 0.9.8; <http://arxiv.org/abs/1207.3907>), UnifiedGenotyper (version 2.2–15)³⁴ and mpileup (version 0.1.18)³⁶. Variants from each caller were then filtered for sites with a minimum quality of 50 and minimum depth of 10. Variants called by a minimum of

two callers were used to filter variants. Surviving variants were annotated using Annovar (downloaded on 5/9/2013)³⁷. A final level of filtration was performed on variants that showed clear clustering by mouse, which were called SNPs and discarded. In *Kras*^{LSL-G12D} mice, MNU-induced G12D mutation of the *WT* allele was clearly distinguished from latent G12D on the *Kras*^{LSL-G12D} allele by observation of a nearby SNP, unique to the *Kras*^{LSL-G12D} allele, in the exome-sequencing reads as well as Sanger sequencing.

Mutation spectra analysis

SNVs in all tumours were annotated by the 96 possible trinucleotide context substitutions (6 types of substitutions x 4 possible flanking 5'-bases x 4 possible flanking 3'-bases) and summed in each tumour, creating a matrix of 82 tumours x 96 substitutions. For hierarchical clustering, these counts were converted to per tumour proportions and clustered by Euclidean distance and similarity computed by nearest neighbor in R. For heatmaps in Fig. 1c and Extended Data Fig. 1, substitution counts were log₁₀ normalized, column scaled and centered on 0. Mutation spectra barplots were created by dividing each totaled type of substitution in each tumour by the total number of successfully sequenced contexts (defined as 10X coverage) in that tumour corresponding to each substitution, retrieved from mpileup of the .bams in samtools. The resulting per-tumour substitution rates were then averaged across all tumours in the respective treatment groups.

Prioritization of high-likelihood driver genes

We explored a recently published gene prioritization approach that specifically addresses the phenomenon of spurious enrichment of longer genes by adjusting for gene expression and replication timing⁴. However, given the scarcity of recurrent variants in our dataset limiting the utility of this approach, we decided to prioritize variants that occurred in genes described by Vogelstein et al. (2013) as known to harbor *bona fide* driver mutations in cancer¹⁹, as well as the recently identified lung cancer driver genes *Fgfr4*, *Map3k9*, and *Pak5*¹⁸. In particular, Vogelstein et al. described a stringent list of 125 driver genes harboring subtle mutations based on the criteria that >20% recorded mutations in oncogenes must be recurrent and missense, and >20% recorded mutations in tumour suppressors must be inactivating. *Mtus1* was chosen for further investigation due to recurrence of missense and nonsense mutations. Variants were compared to known human somatic mutations as available via the COSMIC database³⁸. Briefly, the mouse and human sequences for homologous proteins were pairwise aligned using Clustal Omega³⁹ and the human protein position homologous to the mouse mutation was used to query COSMIC for known missense and nonsense mutations at or surrounding this peptide position. Local conservation was determined after sequence alignment using a +/- 10 amino acid residue window surrounding the substituted amino acid.

Validation of SNVs

SNVs were validated by either Sequenom MassARRAY or conventional Sanger sequencing. SNVs were called validated if they were detected in the tumour but not matched normal DNA. A subset of SNVs which failed both methods for technical reasons was called validated if individual inspection of the aligned reads in tumours and controls strongly

supported validity, as performed in previous studies⁴⁰. Method of validation for SNVs in driver genes is noted in Extended Data Table 2 and SI Table 5. Altogether, validation was attempted on 401 SNVs from the adenomas. A total of 11 failed for technical reasons, and 13 were inconclusive. A total of 17 variants were validated by visual inspection, representing 4.2% of the 401 variants tested. SNVs tested by Sequenom were called inconclusive if the SNV was observed in the tumour but failed in the control, or the SNV was observed in the tumour and not the matched normal control, but was observed in control tissue from another mouse. SNVs tested by visual inspection were called inconclusive if inspection suggested somatic origin, but total variant reads were less than 10. The overall validation rate (excluding inconclusive SNVs) was 87%. The Sequenom validation rate alone was 86%. The vast majority of *Kras* mutations were validated by Sanger sequencing, although a small subset went undetected by this method (SI Table 1) despite confirmation by manual inspection of the alignments, suggesting a higher sensitivity afforded by WES. These patterns confirm previous results on carcinogen-specific mutations in *Kras*^{6,9,10}. Sanger sequencing validation was attempted on 20 randomly selected CGN>A transitions as well as 3 CGN>A transitions in driver genes in the adenocarcinoma samples, 15 of which passed (SI Table 8). Alignments were visually inspected for the remaining 8, all of which supported somatic origin, but only one of which had enough variant reads (≥ 10) to pass. Interestingly, the inconclusive variants and the majority of the validated variants had very low variant read fractions, supporting a hypothesis that the CGN>A mutations were acquired during progression and are represented in subclonal tumour fractions.

Assessment of copy number from read depth

Copy number was estimated from sequencing data using FREEC (version v6.4; <http://bioinfo-out.curie.fr/projects/freec/>). Read depth was compared between tumour and control samples to estimate copy number in 8 kb windows, and subsequently segmented via a LASSO based algorithm⁴¹. FREEC was run with the following parameters: window size, 8 kb; step size, 2.5 kb; contaminationAdjustment = TRUE; noisyData = TRUE; BAF calculation activated. 2.5 kb windows were then aggregated into 15 kb bins by taking the median ratio for all covered windows. Each tumour was profiled against the two *WT* controls used for variant calling. Aggregate profiles were generated for each tumour by the following rules: if either ratio was approximately neutral, the region was considered neutral; if both ratios were aberrant with the same directionality, the more conservative ratio was used; if both ratios were aberrant with different directionality, the region was discarded. Resulting merged ratios were then inspected for high missing rates and low variance, which were then omitted. Additionally, several small regions with evidence of technical artifacts resulting in extremely consistent aberration rates (greater than 50% of samples) across all treatment groups were manually excluded. Particularly, these regions were manually inspected for the existence of large gene families that could account for misalignments and result in spurious aneuploidies. Short spans on chromosomes 1, 4, 6, and 12 were discarded as artifacts.

Histological classification

A small piece of each tumour was collected and paraffin embedded for pathology, sectioned to 6 μm and H&E stained. Histological architecture was classified as either papillary, solid,

or mixed papillary and solid. Solid was defined as histology with marked lack of papillary structure, yet more structure than traditionally solid lung adenocarcinomas in humans. Adenocarcinomas were called based on large size and the presence of the following cytological criteria: tumour cell crowding, scattered mitotic figures, nuclear atypia (enlargement and moderate pleomorphism), nuclear membrane irregularity, and prominent nucleoli. All histology was called by a lung pathologist blinded to the study groups and conditions.

Cell culture, *Mtus1* knockdown, and MTT assay

The mouse lung cancer cell line K493.1, which harbors a *Kras* G12D mutation, was grown in DMEM supplemented with 10% fetal bovine serum (Atlas Biologicals). *Mtus1* was knocked down using 50 nM ON-TARGETplus SMARTpool siRNA (Dharmacon) containing multiple pooled siRNAs targeting all isoform transcripts of mouse *Mtus1* (Cat: L-065229-01). Transfection of siRNA was performed at ~20–40% cell confluence using Lipofectamine-2000 (Invitrogen). In parallel, cells were transfected with control ON-TARGETplus Non-Targeting Pool siRNA (Cat: D-001810-10). RNA was harvested from cells at day 3 after transfection using Trizol reagent (Invitrogen), DNA was removed using the TURBO DNA-free kit (Ambion), and cDNA was synthesized from 500 ng RNA using the Superscript III First-strand Synthesis kit (Invitrogen). qRT-PCR was performed on cDNA using TaqMan Assays-on-Demand (Applied Biosystems) against mouse *Mtus1* (Mm00628662_m1 *Mtus1*) and *b-actin* on the 7900HT Fast Real-Time PCR System (Applied Biosystems). Reactions were performed in quadruplicate, and levels of *Mtus1* were normalized to *b-actin*. Cell proliferation was assayed in 96-well plates (six replicate wells per group) at days 1, 2, and 3 after siRNA transfection using MTT (Invitrogen). Formazan crystals were re-suspended in DMSO, and absorbance was read at 540 nm. Four independent experiments were performed, and a significant increase in absorbance (Wilcoxon rank-sum test) was always seen in the *Mtus1* knockdown compared to control siRNA cells at day 3. One representative experiment is shown in Extended Data Fig. 5b. All protocols were performed following manufacturer's instructions.

Survival analyses in human lung cancer datasets

The TCGA LUAD (human lung adenocarcinoma) and LUSC (human lung squamous cell carcinoma) datasets were downloaded from the UCSC Cancer Genomics Browser (<https://genome-cancer.ucsc.edu>). Illumina HiSeq 2000 RNA Sequencing expression data was used for analyses of gene expression with overall survival. A validation dataset for *MTUS1* expression in lung adenocarcinoma²⁴ was downloaded from <https://caintegrator.nci.nih.gov/caintegrator/>. Analysis of *MTUS1* expression and survival was also repeated in a second squamous cell carcinoma (SCC) dataset⁴², which was downloaded from the UCSC Cancer Genomics Browser. No association between *MTUS1* expression and survival was seen in the SCC datasets (SI Table 3), suggesting that *MTUS1* expression may only have prognostic significance in certain types of lung cancer such as NSCLC. For all survival analyses, clinical covariates of sex, age, cigarette pack years smoked, and stage were included, except in the Shedden, et al. dataset²⁴ where cigarette pack years smoked was not available. Cox regression was performed in R with gene expression as a continuous variable. High and low

expression groups were split about median expression values for plotting Kaplan-Meier curves.

Human versus mouse mutation comparison

Genes included in this comparison were limited to known driver genes (see *Prioritization of high-likelihood driver genes*) harboring mutations in the carcinogen-induced mouse tumours. The TCGA LUAD WES.vcf was downloaded from the UCSC Cancer Genomics Browser (<https://genome-cancer.ucsc.edu>). Only functional SNVs and indels were included. Validated functional SNVs from carcinogen-induced mouse adenomas and adenocarcinomas, and CNAs from the carcinogen-induced adenomas, were used in the comparison. Inclusion of mouse CNAs (6 total) made little difference overall, but were included to emphasize recurrent mutation of Rb1 in the mouse tumours, which had four deletions and two missense SNVs.

Generation of plots

All plots were created using the statistical computing language R (R Core Team (2013). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. <http://www.R-project.org/>). Heatmaps were generated using the heatmap.2 function in the gplots package (Gregory R. Warnes, et al. (2014). *gplots: Various R programming tools for plotting data*. <http://CRAN.R-project.org/package=gplots>), Kaplan-Meier curves were generated using the survival package (Therneau T (2013). *A Package for Survival Analysis in S*. <http://CRAN.R-project.org/package=survival>), and all other plots were made using the ggplot2 package (H. Wickham (2009). *ggplot2: elegant graphics for data analysis*. Springer, New York).

Statistical analyses


The nonparametric Wilcoxon rank-sum test (Mann-Whitney U test) was used in Figures 1, 2, 4, and Extended Data Figures 2, 4, and 5 for testing the alternative hypothesis that two populations of values differ against the null hypothesis that they are the same. This test was chosen due to efficiency in handling both normal and non-normal distributions. The Fisher Exact test was used in the text and in Extended Data Figures 3 and 4 to compare count data between groups, and was chosen for its robust ability to handle high and low ranges of count data. Where appropriate, p-values were adjusted for multiple tests using the Holm's correction for multiple comparisons. Survival analysis in Extended Data Figure 5 is explained in the section "Survival analyses in human lung cancer datasets". All data were visualized in R using summary statistics and basic plotting functions prior to statistical testing, and variance was comparable in all cases where the Wilcoxon rank-sum test was used. All assumptions of statistical tests were met.

Data deposition


The raw.bam files are available at ENA (accession ERP001454). A sample ID key with study names and ENA names is provided in supplementary information (ExomeLungTumorIDs_Key.txt). Variant call format files of SNVs used in analyses in the

paper are provided in supplementary information (Adenomas_variants.txt, Adenocarcinomas_variants.txt).

Extended Data




Extended Data Figure 1. Distinct and consistent mutation spectra across tumours from carcinogen and genetic models
a–c, Stacked heatmaps displaying the mutation spectra of all MNU-induced, **a**, urethane-induced, **b**, and *Kras^{LA2}*, **c**, tumours, shown as normalized frequencies of all 96 possible substitutions. Substitutions are shown below each heatmap, with 5'- and 3'-flanking base context displayed on the top and right, respectively. Tumour ID is shown to the left of each heatmap.




Extended Data Figure 2. Highly specific mutation signatures

a, Breakdown of G>A transitions in MNU-induced tumours. 5'-flanking purine versus pyrimidine G>A substitutions, and 3'-flanking thymidine versus all other G>A substitutions, are highly significant ($p < 0.0003$, Wilcoxon rank-sum test). **b–c**, Breakdowns of A>G transitions, **b**, and A>T transversions, **c**, in urethane-induced tumours. **d–e**, All 96 substitutions in urethane-induced, **d**, and *Kras*^{LA2} tumours, **e**. In **e**, the CGN>A (NCG>T) signature mutations of genomic instability are denoted. Mutation counts per tumour were normalized to total length of sequenced trinucleotide contexts in each tumour and averaged. Error bars represent SEM.




Extended Data Figure 3. *Kras* G12D induces tumours with different histologies than codon 61 mutants

a, Representative papillary, solid, and mixed tumour histologies (200x magnification). **b**, Breakdown of different histologies in each treatment group. Histologies from *Kras*^{LA2} and MNU groups were significantly different than those from urethane, but there was no significant difference between *Kras*^{LA2} and MNU (Fisher Exact test, Holm's correction for multiple comparisons).




Extended Data Figure 4. Germline *Kras* genotype influences mutation specificity in urethane-induced tumours

a, *Kras* mutant alleles for urethane tumours are plotted as colored squares for all three oncogenic alleles detected in these tumours. *Kras* genotype is indicated as either white (*WT*) or black (heterozygous) squares. **b**, Highly significant switch in *Kras* codon 61 mutations between tumours from *WT* mice and *Kras*^{+/-} mice (Fisher Exact test). **c**, No significant difference was seen between the exome-wide rates of causative *Kras* Q61R (CAA>G) and Q61L (CAA>T) mutations between tumours from *WT* and *Kras*^{+/-} mice (Wilcoxon rank-sum test).




Extended Data Figure 5. *MTUS1* is a tumour suppressor in mouse and human lung cancer

a, qRT-PCR quantification of siRNA knockdown of *Mtus1* in a *Kras* G12D mouse lung cancer cell line (K493.1) (Wilcoxon rank-sum test). **b**, MTT assay shows increased growth following *Mtus1* knockdown (Wilcoxon rank-sum test). Four independent trials were performed and growth was significantly increased by day 3 after knockdown in each experiment. One representative trial is shown. **c**, *MTUS1* expression is significantly associated with overall survival in human lung adenocarcinoma, $p=0.00097$, $\chi^2=10.9$. Analysis was performed using clinical covariates gender, age, pack years smoked, and stage.




Extended Data Figure 6. Proportion of tumours with CNAs in each treatment group

Amplifications and deletions were defined as regions with a \log_2 ratio greater than 0.5 or less than -0.5 , respectively. Chromosomes are arranged on the X axis in a head-to-tail formation.



Extended Data Figure 7. Histological confirmation of lung adenocarcinomas
a–b, Representative histologies (400x magnification) of *A/J*, **a**, and *FVB/N*, **b**, adenocarcinomas. Zoom insets show tumour cell crowding and scattered mitotic figures (black arrowheads), nuclear atypia including enlargement and moderate pleomorphism, nuclear membrane irregularity, and prominent nucleoli. Scale bar = 20 μm .



Extended Data Figure 8. Comparison of urethane-signature mutations in adenomas and adenocarcinomas

Urethane A>G transitions (left) and A>T transversions (right) are shown in *A/J* adenocarcinomas, *FVB/N* adenocarcinomas, and *FVB/N* adenomas. Mutation counts per tumour were normalized to total length of sequenced trinucleotide contexts in each tumour and averaged. Error bars represent SEM.

Extended Data Table 1

Treatment groups and lung tumours for WES.

Treatment	<i>Kras</i> Genotype	Tumours (n)	<i>Kras</i> mutations
Urethane	WT	18	Q61R/L/H
	Het	26	Q61R/L/H
MNU	WT	5	G12D
	Het	21	G12D
None	LA2	12	G12D

Extended Data Table 2

Mouse lung adenoma SNVs in established cancer driver genes and *Mtus1*.

Chr	Position	Gene	Exon	Substitution	Consequence	Observed	Tumours	Validated	Validation Method*
12	112662237	Akt1	3	GGA>A	E40K	1	1024T10	Yes	Both
17	72603313	Alk	1	GGG>A	G133R	1	1024T8	Yes	Sequenom
18	34316299	Apc	16	TGT>A	Q2083X	1	1024T8	Yes	Inspection
4	133720797	Arid1a	3	GGA>A	S520F	1	1024T6	Yes	Sanger
4	133686649	Arid1a	15	GAC>G	D1287G	1	33T4	Yes	Sanger
17	5097671	Arid1b	3	GGG>A	P564L	1	1045T4	Yes	Sequenom
17	5337117	Arid1b	18	AGA>A	S1563F	1	1024T3	Yes	Sequenom
17	5337249	Arid1b	18	GGA>A	S1607F	1	1024T7	Yes	Sequenom
2	153393885	Asx1	9	GGG>A	G296R	1	1024T2	Yes	Sequenom
2	153397578	Asx1	11	GGC>A	P430S	1	1024T4	Yes	Sequenom
9	53460891	Atm	46	AGG>A	R2200K	1	75T3	Yes	Sequenom
9	53511883	Atm	13	AGA>A	E648K	1	1024T8	Yes	Sequenom
9	53518635	Atm	9	AGA>A	S367F	1	1024T4	Yes	Both
X	105875634	Atrx	9	GGG>A	G867R	1	1024T3	Yes	Sequenom
17	26190206	Axin1	8	AGC>A	A727T	1	1039T3	Yes	Inspection
11	101549022	Brca1	2	GGA>A	P25S	1	1024T7	Yes	Sequenom
5	150558455	Brca2	21	GGA>A	D2821N	1	1045T1	Yes	Sequenom
5	140882326	Card11	19	GGA>C	E856Q	1	1045T2	Yes	Inspection
9	44164145	Cbl	8	GGA>A	S401F	1	1024T9	Yes	Sanger
7	25286003	Cic	6	AGG>A	G291R	1	1012T3	Yes	Inspection
7	25287831	Cic	9	GGG>A	G481E	1	1024T5	Yes	Inspection
16	4085706	Crebbp	31	GGT>A	P1890S	1	1024T7	Yes	Sequenom
16	4094715	Crebbp	24	GGG>A	P1353S	1	1024T3	Yes	Sequenom
16	4117340	Crebbp	14	GGT>A	T933I	1	1024T1	Yes	Sequenom
17	33913569	Daxx	6	AGA>A	D596N	1	1024T2	Yes	Inspection
12	3899919	Dnmt3a	10	AGC>A	A352T	1	1045T4	Yes	Sequenom
15	81628398	Ep300	15	GGA>A	E974K	1	1024T5	Yes	Inspection
X	95428261	Fam123b	2	AGT>A	V84I	1	1024T4	Yes	Inspection
7	130196315	Fgfr2	9	CAG>G	C401R	1	1012T3	Yes	Inspection
5	33733951	Fgfr3	12	GGC>A	A539T	1	1024T1	Yes	Sequenom
5	33733706	Fgfr3	11	GGT>A	V482I	1	1024T5	Yes	Sanger
13	55160082	Fgfr4	7	GGC>A	A293V	1	1045T7	Yes	Inspection
5	147344556	Flt3	19	TGA>A	E789K	1	1045T4	Yes	Sequenom
6	88204692	Gata2	5	TAC>G	Y376C	1	1024T3	Yes	Sequenom
2	9874578	Gata3	3	GGA>A	E196K	1	1045T4	Yes	Sequenom
5	114952618	Hnf1a	7	GGG>A	P487S	1	1045T5	Yes	Sequenom
1	65161862	Idh1	7	GGC>A	G310D	1	1012T3	Yes	Inspection
19	29302040	Jak2	21	AGT>A	V1010I	1	1024T10	Yes	Sequenom
X	152268847	Kdm5c	19	CAG>T	Q902L	1	33T4	Yes	Sanger

Chr	Position	Gene	Exon	Substitution	Consequence	Observed	Tumours	Validated	Validation Method*
X	152271108	Kdm5c	23	GAC>G	T1179A	1	35T1	Yes	Sanger
5	75647780	Kit	15	AGG>A	P728L	1	1024T2	Yes	Sequenom
4	55530863	Klf4	3	CAG>G	S83G	1	1800T2	Yes	Sequenom
13	111758076	Map3k1	11	AGA>A	D689N	1	1026T1	Yes	Inspection
12	81780619	Map3k9	1	GGG>A	G86S	1	1026T2	Yes	Sanger
12	81724480	Map3k9	10	GGT>A	T778I	1	1026T1	Yes	Sanger
12	81772793	Map3k9	2	AGG>A	R229K	1	75T1	Yes	Sanger
X	101294069	Med12	41	TAC>G	T1985A	1	33T2	Yes	Sequenom
19	6336766	Men1	3	AGG>A	G169R	1	1024T2	Yes	Sequenom
6	17562227	Met	19	CAA>C	K1196Q	1	1790T1	Yes	Sequenom
15	98852106	Mll2	32	GGG>A	P2569S	1	1024T4	Yes	Sequenom
15	98859560	Mll2	15	GGC>A	A1352T	1	1026T2	Yes	Sequenom
11	62343219	Ncor1	30	AGA>A	E1441K	1	1026T2	Yes	Sequenom
11	79425592	Nf1	13	TGT>A	C491Y	1	1024T3	Yes	Sequenom
3	98100211	Notch2	8	GGG>A	P426S	1	1045T2	Yes	Sequenom
4	44691909	Pax5	3	GGG>A	W112*	1	1024T10	Yes	Both
5	75181651	Pdgfra	15	AAT>T	N711I	1	309T1	Yes	Sequenom
5	75187929	Pdgfra	19	TGA>A	D877N	1	1045T1	Yes	Sequenom
17	20962623	Ppp2r1a	13	GGG>A	P523L	1	1024T7	Yes	Sequenom
13	63525046	Ptch1	17	AAC>G	N915S	1	1T2	Yes	Inspection
14	73206017	Rb1	22	GGA>A	S766F	1	1024T7	Yes	Inspection
14	73206083	Rb1	22	GGA>A	S744F	1	1024T5	Yes	Inspection
6	118164756	Ret	17	AGG>A	R970K	1	1024T5	Yes	Inspection
11	87731186	Rnf43	9	AGA>A	R371K	1	1024T8	Yes	Inspection
1	55012160	Sf3b1	6	GGT>A	T203I	1	1045T4	Yes	Sequenom
10	19011651	Tnfaip3	2	GGT>A	T42I	1	1026T2	Yes	Sanger
8	41083460	Mtus1	2	GGG>A	W406*	2	1024T5, 1011T1	Yes	Both
8	41084181	Mtus1	2	CGT>A	T166M	1	1024T7	Yes	Both
8	41015397	Mtus1	7	GGG>A	G902R	1	1039T4	Yes	Both

* Validation Method: Both = Sequenom MassArray and Sanger sequencing. Inspection = manual inspection of alignments

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NCI grants R01 CA111834, U01 CA84244, U01 CA141455 and U01 CA176287 (to A.B.), and partly funded by the Bonnie Addario Foundation. P.M.K.W was supported by the NIH training grant T32 GM007175 and an NSF GRFP award, and is currently supported by an NCI F31 NRSA award. K.D.H was supported by the NIH training grant T32 GM007175, and is currently supported by an NCI F31 NRSA award. D.J.A is supported by Cancer Research UK and the Wellcome Trust. We are greatly appreciative of the help and comments from our colleagues in refining this study and manuscript. We would also like to thank Shon Green, Dr. Tina Yuan, and Dr. Martin McMahon at UCSF Helen Diller Cancer Research Center for kindly providing the cell line K493.1.

References

1. Ciriello G, et al. Emerging landscape of oncogenic signatures across human cancers. *Nat Genet.* 2013; 45:1127–1133. [PubMed: 24071851]
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature.* 2009; 458:719–724. [PubMed: 19360079]
3. Alexandrov LB, et al. Signatures of mutational processes in human cancer. *Nature.* 2013; 500:415–421. [PubMed: 23945592]
4. Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature.* 2013; 499:214–218. [PubMed: 23770567]
5. Johnson L, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature.* 2001; 410:1111–1116. [PubMed: 11323676]
6. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumours of the strain A mouse. *Proc Natl Acad Sci U S A.* 1989; 86:3070–3074. [PubMed: 2654935]
7. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. *Cancer Res.* 2012; 72:2457–2467. [PubMed: 22589270]
8. Jackson EL, et al. Analysis of lung tumour initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev.* 2001; 15:3243–3248. [PubMed: 11751630]
9. Zhang Z, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. *Nat Genet.* 2001; 29:25–33. [PubMed: 11528387]
10. To MD, et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. *Nat Genet.* 2008; 40:1240–1244. [PubMed: 18758463]
11. Govindan R, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. *Cell.* 2012; 150:1121–1134. [PubMed: 22980976]
12. Forkert PG. Mechanisms of lung tumourigenesis by ethyl carbamate and vinyl carbamate. *Drug Metab Rev.* 2010; 42:355–378. [PubMed: 20205516]
13. Kurowska M, Labocha-Pawlowska A, Gnizda D, Maluszynski M, Szarejko I. Molecular analysis of point mutations in a barley genome exposed to MNU and gamma rays. *Mutat Res.* 2012; 738–739. 52–70.
14. Pfeifer GP. Mutagenesis at methylated CpG sequences. *Curr Top Microbiol Immunol.* 2006; 301:259–281. [PubMed: 16570852]
15. Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell.* 2012; 150:264–278. [PubMed: 22817890]
16. Drugan JK, et al. Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. *J Biol Chem.* 1996; 271:233–237. [PubMed: 8550565]
17. Spoerner M, Herrmann C, Vetter IR, Kalbitzer HR, Wittinghofer A. Dynamic properties of the Ras switch I region and its importance for binding to effectors. *Proc Natl Acad Sci U S A.* 2001; 98:4944–4949. [PubMed: 11320243]
18. Fawdar S, et al. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. *Proc Natl Acad Sci U S A.* 2013; 110:12426–12431. [PubMed: 23836671]
19. Vogelstein B, et al. Cancer genome landscapes. *Science (80-).* 2013; 339:1546–1558.
20. Di Benedetto M, et al. Mutation analysis of the 8p22 candidate tumour suppressor gene ATIP/MTUS1 in hepatocellular carcinoma. *Mol Cell Endocrinol.* 2006; 252:207–215. [PubMed: 16650523]
21. Frank B, et al. Copy number variant in the candidate tumour suppressor gene MTUS1 and familial breast cancer risk. *Carcinogenesis.* 2007; 28:1442–1445. [PubMed: 17301065]
22. Zuern C, et al. Down-regulation of MTUS1 in human colon tumours. *Oncol Rep.* 2010; 23:183–189. [PubMed: 19956880]
23. Xiao J, et al. Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. *Oncol Lett.* 2012; 4:113–118. [PubMed: 22807972]

24. Shedden K, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nat Med.* 2008; 14:822–827. [PubMed: 18641660]
25. To MD, et al. Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. *Mol Cancer Res.* 2011; 9:1339–1345. [PubMed: 21807965]
26. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsiichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. *Proc Natl Acad Sci U S A.* 1997; 94:3627–3632. [PubMed: 9108028]
27. McFadden DG, et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. *Cell.* 2014; 156:1298–1311. [PubMed: 24630729]
28. Nuzum EO, Malkinson AM, Beer DG. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. *Mol Carcinog.* 1990; 3:287–295. [PubMed: 2244961]
29. Berndt A, et al. Identification of fat4 and tsc22d1 as novel candidate genes for spontaneous pulmonary adenomas. *Cancer Res.* 2011; 71:5779–5791. [PubMed: 21764761]
30. To MD, Rosario RD, Westcott PM, Banta KL, Balmain A. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. *Oncogene.* 2013; 32:4028–4033. [PubMed: 22945650]
31. Johnson L, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. *Genes Dev.* 1997; 11:2468–2481. [PubMed: 9334313]
32. Varela I, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature.* 2011; 469:539–42. [PubMed: 21248752]
33. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009; 25:1754–60. [PubMed: 19451168]
34. DePristo MA, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet.* 2011; 43:491–8. [PubMed: 21478889]
35. Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol.* 2013; 31:213–9. [PubMed: 23396013]
36. Li H, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* 2009; 25:2078–9. [PubMed: 19505943]
37. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010; 38:e164. [PubMed: 20601685]
38. Forbes SA, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res.* 2011; 39:D945–50. [PubMed: 20952405]
39. Sievers F, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol.* 2011; 7:539. [PubMed: 21988835]
40. Nik-Zainal S, et al. Mutational processes molding the genomes of 21 breast cancers. *Cell.* 2012; 149:979–993. [PubMed: 22608084]
41. Boeva V, et al. Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization. *Bioinformatics.* 2011; 27:268–9. [PubMed: 21081509]
42. Raponi M, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. *Cancer Res.* 2006; 66:7466–7472. [PubMed: 16885343]



Figure 2. Distinct copy number profiles of genetically- and chemically-induced tumours
 Unsupervised, hierarchical clustering of \log_2 transformed read count ratios. *Kras*^{LA2} tumours showed a significantly higher number of CNAs compared to carcinogen-induced tumours ($p = 4.3 \times 10^{-10}$, Wilcoxon rank-sum test). Chromosomes are aligned head to tail on the X axis, starting at the left. Samples are labeled by treatment and genotype, with *Kras*^{+/-} samples appearing as light blue and light red. Sample SNV burden is displayed along the Y axis in greyscale.




Figure 3. Consequential SNVs in high-likelihood driver genes only occur in carcinogen-induced tumours

All missense and nonsense SNVs, amplifications, and deletions in genes listed in Extended Data Table 2 are displayed. *Kras*^{LA2}, urethane-, and MNU-induced tumours are denoted above in green, blue, and red, respectively, with lighter shading denoting *Kras*^{+/-} genotype. SNVs with unequivocal evidence of consequence are bordered in black. All SNVs, excepting those marked with an asterisk, are concordant with the signature mutations of the inducing carcinogen. The bottom panel shows total SNVs per tumour (NS = nonsynonymous, S = synonymous).




Figure 4. Adenocarcinomas show enrichment for a signature of genomic instability
 Breakdown of G>A transitions in *A/J* and *FVB/N* adenocarcinomas reveals significant increases in CGN>A (NCG>T) transition rates over *FVB/N* adenomas ($p = 0.00047$ and 0.0143 , respectively, Wilcoxon rank-sum), despite similar rates and patterns of other G>A transitions. Mutation counts per tumour were normalized to total length of sequenced trinucleotide contexts in each tumour and averaged. Error bars represent SEM.